Key Highlights

  • The stock rose 92.40% to USD 3.29 in regular trading on November 3, 2026, up USD 1.58.
  • No company announcement dated October 30 to November 3, 2026 was identified as the trigger.
  • Interim data on the first 10 patients in the ReSPECT-LMM trial will be presented on November 13, 2026.
  • Trailing twelve-month Revenue was about USD 4.20 million against a net loss of about USD 26.09 million.
  • The company announced a financing Facility of up to USD 20 million on September 10, 2026.

What Moved Cerenome Today (up USD 1.58, 92.40%)

Cerenome (NASDAQ:CNSY) rose 92.40% to USD 3.29 in regular trading on November 3, 2026, a gain of USD 1.58 from the Monday, November 2, 2026 close. The implied prior close is about USD 1.71 (calculated). The screen showed Volume of about 10.25 million shares.

No press release or regulatory filing dated between October 30 and November 3, 2026 was identified as a clear catalyst. The move looks like momentum in a small cap biotech with a clinical data event on the calendar, and the company has not explained it.

What Is the Upcoming Data Event?

According to a company press release dated October 27, 2026, Cerenome will present interim results from ReSPECT-LMM at the 2026 Society for Neuro-Oncology annual meeting in Philadelphia. The poster is scheduled for Friday, November 13, 2026, with a sponsored symposium on November 14, 2026.

ReSPECT-LMM is a Phase 1, open-label, multicenter study of repeated REYOBIQ (rhenium Re186 obisbemeda) doses in leptomeningeal metastases, a condition with no approved therapies. The interim data cover the first 10 patients and include safety, dosimetry and a cerebrospinal fluid tumor cell biomarker. The release disclosed no efficacy results and called the data preliminary. The company aims to start a Phase 2 dose randomization study in 2027.

What Does Cerenome Do and How Are Results Trending?

Cerenome is the new name of Plus Therapeutics, which began trading as CNSY on August 3, 2026 after a rebrand announced on July 31, 2026. It describes itself as an integrated central nervous system oncology company with a CSF-based diagnostic called CNSide, the investigational radiotherapeutic REYOBIQ and a data and AI platform.

Recent company updates include a dual mechanism of action disclosure for REYOBIQ on October 21, 2026, an in-network agreement with Florida Blue on October 8, 2026 and a launch of CNSide molecular profile tests on October 6, 2026. The company guided to about USD 1.55 million of CNSide third quarter gross billings on September 30, 2026. Public data show trailing twelve-month revenue of about USD 4.20 million, down 21.0%, and a net loss of about USD 26.09 million.

What Are the Balance Sheet and Financing Risks?

The company announced on September 10, 2026 a financing facility of up to USD 20 million with royalty-based repayment. A shelf registration statement that became effective on June 5, 2026 also leaves room to issue new equity, so dilution is a continuing risk. The sources reviewed did not give a current cash balance.

As a Penny Stock trading at USD 3.29 after a one-day gain of 92.40% invites sharp reversals. Early stage trial data come from small patient numbers, and investigational therapies carry a high rate of setbacks. The screen Market Capitalisation of about USD 12.98 million appears to reflect an earlier price near USD 1.71 and is not used as a current value.

What to Watch Next

The key date is November 13, 2026, when interim ReSPECT-LMM data are presented. The detail on safety, dosimetry and the biomarker will show whether the Phase 2 plan in 2027 looks well supported.

Investors should also follow the quarterly report, any new payer agreements for CNSide, a Medicare rate decision and any Equity offering announced after the rally.